Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.42 |
| ▸ | RXRB | P28702 | 11/20 | 0.42 |
| ▸ | RARG | P13631 | 9/20 | 0.42 |
| ▸ | RXRG | P48443 | 8/20 | 0.42 |
| ▸ | RARB | P10826 | 8/20 | 0.42 |
| ▸ | RARA | P10276 | 6/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.38 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7622765 | 0.84 | RXRA (0.48) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL15347776 | 0.82 | RXRA (0.50) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL6678059 | 0.82 | RXRA (0.49) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL9867812 | 0.82 | PTK2 (0.44) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL31686025 | 0.79 | TSHR (0.33) | — | |
| SCHEMBL8308844 | 0.78 | RXRA (0.43) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL6939291 | 0.78 | RXRA (0.36) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL5009416 | 0.78 | RXRA (0.41) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL9054118 | 0.78 | RARB (0.47) | RXRARXRBRARGRXRGRARB | |
| SCHEMBL15348324 | 0.78 | RXRA (0.51) | RXRARXRBRARGRXRGRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107304172-B | Octahydroanthracene compound and preparation method and application thereof | 沈阳药科大学 | 2020-04-03 | — | — | CN | disclosed |
| US-10399931-B2 | Octahydroanthracene compound, preparation method and application thereof | SHANDONG XINHUA PHARMACEUTICAL CO., LTD. (CN) | 2019-09-03 | — | — | US | disclosed |
| US-20190071393-A1 | Octahydroanthracene Compound, Preparation Method and Application Thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2019-03-07 | — | — | US | disclosed |
| US-4123469-A | Process for production of bicyclic compounds | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1978-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399931-B2 | Octahydroanthracene compound, preparation method and application thereof | ODC1, OTC, TMT1A | RXRA 2834/4885RXRB 2239/4885RARG 3904/4885 |
| US-20190071393-A1 | Octahydroanthracene Compound, Preparation Method and Application Thereof | ODC1, OTC, TMT1A | RXRA 2834/4885RXRB 2239/4885RARG 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.